Aqua Bio Technology ASA

Aqua Bio Technology ASA

4.89
NOK
0.00
(0.00%)
68.45MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
34.4
7.03
2.75
- -
8.69
6.31
3.45
1.37
4.05
16.95
30.06
7.71
0.53
- -
Basic EPS, GAAP
20.32
6.56
124.86
10.46
-114.91
-276.27
-51.19
-45.29
-49.61
-45.27
-34.33
-267
38.6
- -
Free Cash Flow per Basic Share
38.72
37.5
142.38
181.62
-123.77
-126.3
-66.68
-41.49
-64.46
-37.33
-33.77
-42.09
-3.22
- -
Dividend per Share
- -
- -
45.49
121.1
44.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
471.77
474.54
553.24
442.83
276.21
-1.42
23.78
22.57
45.26
4.49
90.24
-49.51
-0.16
2.68
Tangible Book Value per Share
242.53
303.76
497.13
413.98
246.64
-2.52
23.78
-2.56
15.54
-126.26
-82.92
-54
-0.16
2.68
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
3
6
Sales/Revenue/Turnover
5
1
- -
- -
1
1
1
- -
2
7
18
10
1
- -
Operating Margin (%)
37.38
-55.44
4,017.74
- -
-1,225.7
-2,091.42
-1,472.24
-3,624.12
-1,158.56
-295.17
-159.1
-340.36
-892.64
- -
Depreciation Expense
6
6
6
4
1
1
- -
- -
1
2
4
175
7
- -
Net Income, GAAP
3
1
17
1
-16
-38
-13
-15
-19
-19
-21
-363
98
- -
Effective Tax Rate (%)
- -
- -
- -
34.5
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
59.07
93.33
4,545.43
- -
-1,323.01
-4,380.42
-1,482.44
-3,308.89
-1,225.41
-267.01
-114.22
-3,461.83
7,297.73
- -
Working Capital
58
60
71
57
34
-1
7
3
10
-12
-71
-174
-126
-3
LT Debt
6
3
2
1
1
- -
- -
- -
- -
1
24
77
- -
73
Total Equity
66
66
77
62
39
- -
7
8
19
2
86
-108
- -
41
Return on Invested Capital (%)
2.5
-0.76
- -
2.58
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
4.36
1.82
- -
2.81
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
4.41
1.39
24.4
2.11
-32.02
- -
- -
-187.98
-141.43
-182.19
-47.98
- -
- -
- -

Capital Structure

NOK

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
ST Debt
109
109
- -
LT Borrowings
- -
- -
73
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
15
Market Capitalization
65
71
68

Working Capital

NOK

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
Total Current Assets
12
3
5
Cash, Cash Equivalents & STI
3
2
4
Accounts Receivable, Net
7
- -
1
Inventories
2
- -
- -
Total Current Liabilities
138
130
8
Payables & Accruals
- -
- -
- -
ST Debt
109
109
- -
Deferred Revenue
- -
- -
- -

Growth Rates

NOK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
26.16%
843.97%
-99.55%
Free Cash Flow
0.89%
34.33%
-85.77%
Net Income, GAAP
33.7%
308.35%
-126.89%
Sales/Revenue/Turnover
- -
126.59%
-87.24%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10
2025
- -
- -
1
2026
- -
- -
- -

Semi-annual Earnings Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-267
2025
- -
- -
38.6
2026
- -
- -
- -

Semi-annual Dividends Per Share

NOK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

CEO
Kristian Flaten
Full Time Employees
6
Sector
Process industries
Industry
Chemicals: major diversified
Address
Oslo Norway
IPO Date
Dec 10, 2007
Business
Aqua Bio Technology ASA is a Norway-based biotechnology and commercial distribution company that researches, develops, and commercializes sustainable bioactive ingredients and personal care products, alongside providing international logistics and e-commerce fulfillment services. The company operates through two core business divisions: Biotechnology and Skincare, and Logistics and Distribution. Its comprehensive product and service portfolio comprises proprietary marine- and botanical-derived cosmetic active ingredients, including Aquabeautine XL (a patented skin renewal and exfoliating enzyme derived from salmon hatching fluid) and Spirulysat (a purified spirulina microalgae antioxidant extract); proprietary and licensed skincare product lines, including Moana-Organic skincare and Cuvget-Arctic skincare formulations; third-party skincare and personal care brand marketing and distribution across retail, dermatological clinic, and professional channels in the Nordic region and broader Europe; cross-border freight forwarding, air shipping, and sea transport services; dedicated e-commerce shipping solutions and package forwarding connecting North American retailers to European consumers through its JetCarrier subsidiary; third-party logistics (3PL) services, automated warehousing, and integrated e-commerce order fulfillment plugins for commercial merchants; and comprehensive international customs clearance and brokerage services. Founded in 2000 and headquartered in Oslo, Norway, Aqua Bio Technology ASA serves cosmetic ingredient manufacturers, pharmaceutical and dermatological distributors, commercial e-commerce retailers, and retail consumers primarily across the Nordic countries, Europe, the Middle East, and North America. In recent developments, the company executed a major strategic expansion by acquiring cross-border logistics and customs specialist JetCarrier AS in late 2024, significantly bolstering its supply chain infrastructure and recurring revenue profile. Following an operational and portfolio review in May 2025, Aqua Bio Technology streamlined its business footprint by divesting retail and distribution subsidiaries Coverbrands AS, Ovalen AS, and 3D Innovation Nordic AS, while discontinuing capital allocation to non-core retail entities including Skinteam Norge AS. To optimize its capital structure and support its ongoing logistics and biotech operations, the company implemented several private placements, subsequent share offerings, and debt-to-equity conversions throughout 2025 and 2026.